All posts by imreal

Catalent to Present on Integrated UpTempoSM Gene Therapy Development Platform at Upcoming ASGCT Annual Meeting


Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced that George Buchman, Ph.D., Vice President, Pre-Clinical and Process Development, will present at the upcoming 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), which is being held at the Los Angeles Convention Center on May 16-20, 2023.

Dr. Buchman’s presentation, on Friday, May 19, at 4:30 p.m. PDT, is entitled “One-stop Integrated Viral Vector Platform for Speed to Clinic,” and will focus on a consolidated and standardized platform to help fast-track AAV vectors to the clinic with a scalable CGMP-ready process. The complete UpTempo℠ AAV platform, which was re-launched in its expanded form in March 2023, provides increased consistency and efficiency, reducing the time to manufacture clinical-quality drug product to just nine months, while delivering a process that will readily advance to late-stage CGMP manufacture.

Dr. Buchman works in Catalent’s Cell & Gene Therapy business, which provides research services and process development and enables the translation of programs into clinical trials and commercial CGMP manufacturing. He has worked more than 30 years in the biotech industry, including at Life Technologies (now Thermo Fisher Scientific), Celera Genomics, and GeneLogic. Dr. Buchman obtained his bachelor’s degree in biochemistry from Albright College, Reading, Pennsylvania, and his doctorate in biochemistry from the University of Maryland.

Catalent will also be exhibiting at the conference, in booth 229. To find out more information about this event, visit https://www.catalent.com/events/asgct-annual-meeting-2023/ and to find out more about Catalent’s UpTempo AAV platform, visit Catalent.com/UpTempo.

About Catalent Cell & Gene Therapy 

Catalent Cell & Gene Therapy is an industry-leading technology, development, and manufacturing partner for advanced therapeutics. Its comprehensive cell therapy portfolio includes a wide range of expertise across a variety of cell types including CAR-T, TCR, TILs, NKs, iPSCs, and MSCs. With deep expertise in viral vector development, scale-up and manufacturing for gene therapies and viral vaccines, Catalent is a full-service partner for plasmid DNA, adeno-associated viral (AAV), lentiviral and other viral vectors, and oncolytic viruses. As an experienced and innovative partner, it has a global network of dedicated, development, clinical, and commercial manufacturing facilities, including an EMA- and FDA-licensed viral vector facility, and fill/finish capabilities located in the U.S. and Europe. With integrated solutions for plasmid DNA, viral vectors, and autologous and allogeneic cell therapies through clinical trial packaging and logistics, Catalent can provide full supply chain control, helping innovators get their advanced therapies to patients, faster.

About Catalent

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.

Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians.

Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

Cancer Nursing Today Announces Its Inaugural CARE Award


Cancer Nursing Today, a Mashup Media, LLC property, is pleased to announce the inaugural Cancer Nursing Today CARE Award, a recognition created to thank and give back to the oncology nurses who provide such important cancer care across the continuum.

Cancer Nursing Today knows that patients rely on their oncology nurses and understands the leadership role nurses have on multidisciplinary teams. Cancer Nursing Today is also aware of the implications of “The Great Resignation” of 2021, wherein 1 in 4 health care workers resigned. The nature of cancer care and the extreme demands of the job had already caused many oncology nurses to experience burnout, and combined with the impact of The Great Resignation, the loss of nursing staff was and continues to be tremendous.

“It takes a village to fight cancer. For me, it has been a privilege to be an oncology nurse and to celebrate the recognition of my peers through this new Cancer Nursing Today CARE Award,” said oncology nurse and Cancer Nursing Today contributor Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®, owner of beyond Oncology Education, LLC.

Cancer Nursing Today established the CARE Award to remind and affirm for these nurses that resilience and role modeling are not only necessary but essential to providing high-level patient care.

“It is important for us to recognize the essential work oncology nurses do and the significant contributions they make to patient care and the oncology community,” said JC Landry, CEO of Mashup Media. “The CARE Award is a way for us to show our support for these indispensable members of the health care team.”

The award recognizes an oncology nurse who demonstrates:

  • Commitment to professional growth
  • Attention and dedication to role modeling
  • Resilience in uncertain and strenuous times
  • Emotional intelligence in every situation

Nominees should demonstrate role modeling and/or advocacy within their community or organization related to clients, patients, colleagues, or the environment.

“This Cancer Nursing Today CARE Award is different from other oncology nursing awards, as the peer nomination process is simple; there’s no lengthy essay required. Nurses in all areas of practice along the cancer care continuum are eligible to win,” said DeMeyer.

The winner of the Cancer Nursing Today CARE Award will receive a prize (valued at $1,000) and be recognized by Cancer Nursing Today for their commitment to this incredibly important profession.

Nominate a deserving colleague now through May 31 at 11:59 PM EST.

Visit the https://cancernursingtoday.com/Cancer Nursing Today website to learn more.

###

About Mashup Media, LLC

Mashup Media, based in Manalapan, NJ, is a multimedia publishing company passionate about providing health care professionals with a platform to further publicize their work. Driven by data and analytics, Mashup Media produces cutting-edge products that deliver content from trusted sources and industry thought leadership. To learn more, visit mashupmediallc.com.

About Cancer Nursing Today

Cancer Nursing Today (CNT) delivers critical news and information to support oncology nurses throughout their education and careers, with the goal of advancing oncology treatments and care and promoting the nurse’s role in enhanced patient outcomes and quality of life. The robust digital platform provides cutting-edge cancer research, conference proceedings, practice updates, and published literature. In addition to its powerful website, CNT leverages e-newsletters and social media to highlight the best content from key opinion leaders in the field. Learn more at https://cancernursingtoday.com/cancernursingtoday.com.

Share article on social media or email:

Ideal Option Launches Mobile Addiction Clinic in Rural Idaho


Ideal Option, a national leader in evidence-based medication-assisted treatment for substance use disorder, has been awarded grant funding from the Idaho Department of Health and Welfare (DHW) to operate a mobile clinic for addiction treatment and prevention of HIV, STI and Hepatitis. The mobile clinic will be providing services in the parking lot of the Albertsons® grocery store in Rexburg on Tuesdays and Wednesdays. The mobile clinic is staffed with a registered nurse and medical assistant who will provide information about SUD treatment and prevention of HIV, STI and Hepatitis. They will also facilitate lab testing and access to an addiction medicine provider via telehealth. Patients can enroll in the Ideal Option program and start on FDA-approved medications for substance use disorder, filled by Albertsons pharmacy, on the same day. In addition to the mobile clinic at Albertsons, Ideal Option has opened a satellite office location in Rexburg – also grant-funded – where patients can be seen on Thursdays, or if inclement weather prevents operation of the mobile clinic.

“Ideal Option’s mission has always been to deliver low-barrier services to underserved communities,” said Yuki Yang, VP of behavioral health and partner operations. “We are therefore excited to partner with the Idaho DHW on this innovative approach to expanding access to life-saving prevention and treatment for SUD and associated risk in rural Idaho.”

The Ideal Option mobile clinic is now seeing new and existing patients on Tuesdays and Wednesdays, 9 a.m. – 4 p.m. and is located in the Albertsons parking lot at 490 N 2nd E, Rexburg, ID 83440. The satellite office location is seeing new and existing patients on Thursdays, 9:30 a.m. – 4:30 p.m. and is located at 124 E. Main St., Rexburg, Idaho 83440.Most forms of insurance are accepted, including Medicare and Medicaid, and patients who wish to stop using pain pills, fentanyl, heroin, alcohol or other substances, including methadone, are welcome.

Patients can walk-up to the mobile clinic to make an appointment or be seen same-day, or schedule an appointment in advance by calling 1.877.522.1275 or visiting http://www.idealoption.com.

About Rexburg Grant Funding

The project described was supported by Grant 93.788 State Opioid Response from Substance Abuse and Mental Health Services Administration. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department, the Department of Health and Human Services, or the Substance Abuse and Mental Health Services Administration.

About Ideal Option

Headquartered in Kennewick, Washington, Ideal Option was founded in 2012 and has since helped more than 65,000 patients through a network of over 90 office-based medication-assisted treatment (MAT) clinics across 11 states. With a mission to serve under-served communities, Ideal Option accepts most forms of insurance including Medicaid and Medicare. Financial assistance and payment plans are also available. Ideal Option’s team of medical providers carry certifications in Addiction and Emergency Medicine, Internal, OB/GYN, and Family Medicine, among other specialties. The company also employs social workers, caseworkers, counselors, and mental health practitioners. This holistic approach helps drive positive outcomes, including family stability, stable housing, improved overall health, and reduced rates of recidivism. In all the communities it serves, Ideal Option collaborates with existing stakeholders and providers to improve the continuum of care. This approach includes partnerships with emergency rooms and county jail systems, where individuals with substance use disorder often appear, as well as collaborating with numerous support agencies and municipal programs addressing social needs such as housing, mental health, and nutrition support.

Share article on social media or email:

Inheritance of Hope encourages all to be intentional on National Legacy Day™


Inheritance of Hope believes that “every family deserves a legacy.” No matter your age or season of life, your legacy matters and should be shared with others.

On May 21, 2023, Inheritance of Hope will celebrate its third annual National Legacy Day™.

Inheritance of Hope (IoH) was founded on May 21, 2007 by Kristen and Deric Milligan. Faced with a rare terminal illness, Kristen looked for resources for her young family but surprisingly found none. She and her husband decided to create resources of their own and share them with others. 16 years later, the national charity continues to inspire hope and encourage all to build an intentional legacy. Each year on May 21, IoH celebrates its founding with National Legacy Day™ – a day focused on legacy and being intentional.

This year, all are invited to join in on social media by sharing and tagging someone who has impacted their life. Everyone has been impacted by someone and IoH encourages you to share with others. Visit NationalLegacyDay.org for a downloadable social media graphic to share & tag on National Legacy Day™ with #NationalLegacyDay #InheritanceOfHopeInheritance of Hope believes that “every family deserves a legacy.” No matter your age or season of life, your legacy matters and should be shared with others.

Join in on National Legacy Day™! Learn more >>

Share article on social media or email:

LM Medical NYC – (Facial Plastic Surgery and Dermatology Specialists) Physicians are Selected as a Castle Connolly 2023 Top Doctors®


News Image

“We are so honored to be recognized by our peers for this award,” says Dr. Lesley Rabach.

For patients seeking non-surgical medical treatment for dermatological needs or wanting to explore cosmetic surgery, LM Medical NYC offers the best of both worlds. As founders of the practice, Dr. Lesley Rabach, facial plastic surgeon, and Dr. Morgan Rabach, a dermatologist, provide the highest-quality medical, surgical and cosmetic care for patients. They are both proud to be featured as “Top Doctors” for 2023 by Castle Connolly in their medical fields. Physicians who receive this impressive award are among the very best in their specialties. The education, training, hospital appointments and disciplinary history of Dr. Lesley Rabach and Dr. Morgan Rabach were rigorously screened by the Castle Connolly physician-led research team. Castle Connolly publishes its list of Top Doctors at http://www.castleconnolly.com, as well as in a wide variety of partner publications, magazines and affiliate websites. The doctors who are listed in their books and directories were nominated by peers and put through an extensive evaluation process.

At LM Medical NYC, patients receive the benefit of access to two top physicians in their respective medical fields, all at one state-of-the-art facility. Dr. Lesley Rabach is an Ivy League trained expert facial plastic and reconstructive surgeon, and board certified in both facial plastic surgery and otolaryngology-head and neck surgery. Her surgical training included a fellowship sponsored by the American Academy of Facial Plastic Surgery and a residency and internship in Otolaryngology-Head and Neck Surgery at Yale New Haven Hospital. She received her Medical Degree from Drexel University College of Medicine and her undergraduate degree from Brown University. Her extensive education, training and experience have earned accolades in her field, and she has been published in various medical journals. Dr. Morgan Rabach has been nationally recognized for her many accomplishments in dermatology and aesthetics. In addition to her private practice, she is a clinical assistant professor of Dermatology at The Icahn School of Medicine at Mount Sinai Hospital. She graduated from Brown University with Honors in Biology, earned her medical degree from NYU- School of Medicine, completed her medical internship at Yale New Haven Hospital and she served as chief resident during her dermatology residency at SUNY Downstate Medical Center. Dr Morgan Rabach has received many top rankings in her field and has a substantial media presence in well-known beauty publications around the world.

“We are so honored to be recognized by our peers for this award,” says Dr. Lesley Rabach.

More about LM Medical NYC:

LM Medical NYC’s clinic is located at 33 Fifth Avenue #1B in New York, NY, and provides cutting-edge cosmetic surgery and skin care treatments As sisters and founders of the practice, Dr. Lesley Rabach and Dr. Morgan Rabach combine their expertise in facial plastic surgery and dermatology, to provide a customized approach to meet each patient’s personal needs. LM Medical NYC has created a comfortable, upscale atmosphere, providing many services, ranging from the latest in clinical dermatology treatments to non-invasive cosmetic injections and youthful makeovers with plastic surgery. For more information or to schedule a consultation or appointment, please call 212-770-2272, or visit http://www.lmmedicalnyc.com.

Share article on social media or email:

Hammes ranked as No. 1 developer in 2023 Modern Healthcare Construction & Design Survey


News Image

To be ranked as the nation’s top developer by Modern Healthcare’s Construction & Design Survey for 20 years is an incredible accomplishment that reflects the collective expertise and value that Hammes brings to our healthcare provider clients.

The Modern Healthcare 2023 Construction & Design Survey recognized Hammes as the nation’s No. 1 healthcare developer. This marks the 25th consecutive year in which Hammes was ranked as one of the top healthcare developers, with 20 of those years being in the No. 1 position.

The annual Modern Healthcare Construction & Design Survey, first published in 1980, ranks development firms based on the dollar volume of healthcare construction projects completed in the previous calendar year. Projects include outpatient and inpatient projects spanning new construction as well as expansions and renovations.

Last month, Hammes was also ranked as the No. 1 developer in the Revista 2023 Outpatient Healthcare Real Estate Development Report, which measures outpatient development activity. This is the first year the same company ranked as No. 1 in both surveys since the inception of the annual Revista report in 2017.

“To be ranked as the nation’s top developer by Modern Healthcare’s Construction & Design Survey for 20 years is an incredible accomplishment that reflects the collective expertise and value that Hammes brings to our healthcare provider clients,” said Nancy Connolly, President of Hammes Healthcare. “We are grateful to our incredible team members as well as our clients and industry partners who we have the privilege to work with on truly transformative healthcare projects.”

About Hammes

Founded in 1991, Hammes is a vertically integrated real estate solutions platform specializing in healthcare real estate strategy and planning, project management, development, investment, and property management. As a testament to our deep healthcare industry experience, Hammes has been recognized as one of the nation’s leading healthcare developers by Modern Healthcare’s Construction & Design Survey for 25 consecutive years—including 20 years as No. 1— and by Revista’s Outpatient Healthcare Real Estate Development Report. Headquartered in Milwaukee, Wisconsin, Hammes provides services through a network of regional offices strategically located across the United States. http://www.hammes.com

Share article on social media or email:

Caring Transitions Signs Agreement for New Location in Carrollton Continues Impressive Momentum


“Now, we want to accelerate growth because we believe there should be a Caring Transitions location in every market to serve seniors and their families through life’s stages,” said Caring Transitions President Ray Fabik.

Caring Transitions, the franchise that provides older adults and their families with the most trusted, respected and comprehensive downsizing, right-sizing, estate sales and online auctions, and move management solutions in the industry, is continuing its recent momentum with the signing for a new location in Carrollton, Texas. In 2022, the brand signed over 40 new franchise owners and entered 20 new cities, making significant strides towards its goal of reaching 400 units in the next five years. So far this year, Caring Transitions has signed 12 new franchise agreements across the country.

“Our growth just keeps getting better every year,” said Caring Transitions President Ray Fabik. “I hear phrases like pandemic-proof and recession-proof, and while I don’t like to use those words, our brand has certainly shown itself to be very resilient. We are really an essential service. When the economy turns even a little bit, people still need to take care of their parents. Our business continues to accomplish big things in light of whatever happens out there. When you look back at the last three years, it has been challenging, but we continue to have double-digit growth year after year.”

As the nation’s largest provider of senior-relocation services, Caring Transitions is increasingly making waves in the $832.8 billion industry, as there are very few businesses specifically equipped to help seniors move from their homes to a care facility or to manage the relocation or sale of all personal belongings. Caring Transitions helps seniors relocate by spending time at their homes, helping them pack and organize their belongings, then moving those belongings to the new home and setting them up in a way that feels comfortable.

Willette Glenn, the franchise owner behind the new Carrollton signing, says they are excited to bring these much-needed services to their community. The deal was closed by Shawn Harrison, Director of Franchise Development.

Glenn is a IT Director for Pepsico. Her emphasis on customer satisfaction has resulted in many awards and accolades throughout her 26 year career. Glenn resides in Little Elm, TX with her husband and their two daughters.

Glenn joins a powerhouse group of owners in the North Dallas Suburbs. While the Fort Worth area is saturated with owners, there are still more opportunities to own a Caring Transitions in the metro-Dallas neighborhood.

Now, with more and more qualified and passionate franchisees like Glenn signing on to join the system, Fabik says Caring Transitions shows no signs of slowing down.

“We know that we have a great brand and that Caring Transitions ownership can be a great fit for someone who is tired of their corporate job and wants control of their own destiny, wants to own a business that is truly making a difference in communities, or wants to apply their skill set to working in the senior or auction space,” Fabik said. “Now, we want to accelerate growth because we believe there should be a Caring Transitions location in every market to serve seniors and their families through life’s stages.”

Caring Transitions has identified these states as priorities for franchise development: Colorado, Connecticut, Florida, Maine, Massachusetts, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, Pennsylvania, Rhode Island, Texas and Vermont.

Fees to open a Caring Transition range from $58,912 to $82,712. To learn more about franchising with Caring Transitions, visit https://strategicfranchising.com/caring-transitions/.

ABOUT CARING TRANSITIONS:

Caring Transitions provides older adults and their families with the most trusted, respected and comprehensive downsizing, right-sizing, estate sales and online auctions, and move management solutions in the industry. Founded in 2006, the brand is committed to helping people in a compassionate and caring manner during life’s many transitions while providing a total and easy solution for clients in their time of need. Through their proprietary online sales platform, CTBIDS, Caring Transitions also prepares clients for the process of liquidating assets through their own online estate sales auction site. With over 250 locations, Caring Transitions’ compassionate, experienced professionals minimize stress and relieve the burdens of life’s transitions. To learn more visit https://www.caringtransitions.com/

Share article on social media or email:

A-Alpha Bio and Lawrence Livermore National Laboratory expand collaboration to accelerate antibody discovery and development for biothreats


A-Alpha Bio

“Our collaboration with the A-Alpha Bio team leverages their platform and expertise toward state-of-the-art computational models that will accelerate drug discovery.”

A-Alpha Bio, a synthetic biology and machine learning company that measures and engineers protein-protein interactions, and Lawrence Livermore National Laboratory (LLNL), a federally funded research and development center, today announced their intention to collaborate to combat multiple pathogen families of concern. To enable this work, A-Alpha Bio has been awarded an additional $2.4M sub-contract from the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in support of the Generative Unconstrained Intelligent Drug Engineering (GUIDE) Program, which the company will use to generate large-scale and quantitative protein-protein interaction (PPI) data and support LLNL’s advanced high-performance computational models for antibody discovery and development.

In support of DOD, over the past year, A-Alpha and LLNL have measured tens of millions of protein interactions between antibodies and coronavirus variants using A-Alpha Bio’s AlphaSeq platform. The experimental data has proven valuable for building and refining LLNL’s computational models for predicting antibody sequences that bind to current and possible future variants of concern. Beyond the pandemic, there is a well-recognized need to ensure preparation for other potential biological threats. Under the GUIDE program, A-Alpha and LLNL will focus their efforts to generate antibody-antigen binding data and train predictive Machine Learning (ML) models for multiple pathogen families prioritized by the DOD.

A-Alpha Bio’s AlphaSeq platform represents the first large-scale and quantitative approach for measuring protein-protein interactions. The AlphaSeq platform can simultaneously measure millions of interactions between antibodies and antigens to determine properties like affinity, specificity, cross-reactivity, and epitope engagement. These data are particularly valuable for training and validating ML models aimed at predicting desirable antibody sequences for therapeutic development. Under the new funding, the teams will work on 5 selected pathogen families that are considered biothreats.

Antibody libraries from LLNL and others will be synthesized and cloned into the AlphaSeq platform to measure all pairwise interactions between each antibody and a library of antigen variants. LLNL will use the binding data to train and refine ML models that learn the affinity landscape across antibody and antigen sequence space. Antibodies with desirable in silico binding profile predictions will be synthesized and tested in subsequent AlphaSeq assays for validation and refinement. Highly predictive ML models will enable computational design of antibodies against never before seen pathogen variants, reducing the response time for future biothreats.

“Based on our experience working with the LLNL team and the computational resources and knowhow that they bring, we are excited to tackle multiple pathogen families beyond COVID,” said Dr. David Younger, Co-Founder and CEO of A-Alpha Bio. “This expanded scope underscores the value of large-scale and high-quality antibody-antigen binding data for training ML models and the importance of rapid experimental iteration to test and refine those models.”

LLNL’s platform integrates world-class high-performance computing and simulation, machine learning, structural bioinformatics, and multi-objective optimization to perform in silico antibody and antigen design and optimization. Critical to these computational models is antibody-antigen binding data that can be experimentally determined using AlphaSeq.

“The AlphaSeq platform can rapidly measure millions of antigen-antibody binding affinities, providing data for our high-performance computational models and enabling accurate binding predictions,” said Daniel Faissol, Principal Investigator for AI-Driven Development of Biologic Countermeasures at LLNL. “Our collaboration with the A-Alpha Bio team leverages their platform and expertise toward state-of-the-art computational models that will accelerate drug discovery.”

About A-Alpha Bio

A-Alpha Bio uses synthetic biology and machine learning to measure, discover, predict, and engineer protein-protein interactions.

The company’s AlphaSeq platform applies synthetic biology to experimentally measure millions of protein-protein interaction affinities simultaneously. Protein binding data is incorporated into the company’s AlphaBind platform to train machine learning models that predict binding from sequence. A-Alpha Bio uses both platforms to discover and optimize high-impact therapeutics for their own pipeline and in partnership with industry leaders.

A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washington’s Institute for Protein Design and Center for Synthetic Biology. To learn more, please visit: https://www.aalphabio.com/

About Lawrence Livermore National Laboratory

Founded in 1952, Lawrence Livermore National Laboratory provides solutions to our nation’s most important national security challenges through innovative science, engineering and technology. Lawrence Livermore National Laboratory is managed by Lawrence Livermore National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration.

About the JPEO-CBRND

The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) mission is to provide an integrated layered chemical, biological, radiological, and nuclear defense capabilities to the Joint Force across combined Joint All-Domain Operations. JPEO-CBRND’s goal is to enable the Joint Force to fight and win unencumbered by a CBRN environment. This contract was funded by the Joint Project Lead for CBRND Enabling Biotechnologies (JPL CBRND-EB) in collaboration with the Department of Energy (DOE) under agreement # A2210-021-089-033253. To learn more about JPEO-CBRND, visit: https://www.jpeocbrnd.osd.mil/, or follow JPEO-CBRND on social media @JPEOCBRND.

Share article on social media or email:

Caring Transitions Signs Agreement for New Location in Raleigh, NC, Continues Impressive Momentum


“We know that we have a great brand and that Caring Transitions ownership can be a great fit for someone who is tired of their corporate job and wants control of their own destiny,” Caring Transitions President Ray Fabik said.

Caring Transitions, the franchise that provides older adults and their families with the most trusted, respected, and comprehensive downsizing, right-sizing, estate sales, and online auctions, and move management solutions in the industry, is continuing its recent momentum with the signing for a new location in the Raleigh suburb of Fuquay-Varina, North Carolina. In 2022, the brand signed over 40 new franchise owners and entered 20 new cities, making significant strides toward its goal of reaching 400 units in the next five years. So far this year, Caring Transitions has signed 12 new franchise agreements across the country.

“Our growth just keeps getting better every year,” said Caring Transitions President Ray Fabik. “I hear phrases like pandemic-proof and recession-proof, and while I don’t like to use those words, our brand has certainly shown itself to be very resilient. We are really an essential service. When the economy turns even a little bit, people still need to take care of their parents. Our business continues to accomplish big things in light of whatever happens out there. When you look back at the last three years, it has been challenging, but we continue to have double-digit growth year after year.”

As the nation’s largest provider of senior-relocation services, Caring Transitions is increasingly making waves in the $832.8 billion industry, as there are very few businesses specifically equipped to help seniors move from their homes to a care facility or to manage the relocation or sale of all personal belongings. Caring Transitions helps seniors relocate by spending time at their homes, helping them pack and organize their belongings, then moving those belongings to the new home and setting them up in a way that feels comfortable.

Becky and Steve Shelton, the franchise owners behind the new Fuquay-Varina signing, say they are excited to bring these much-needed services to their community. The deal was closed by Susan Walker, Senior Director of Franchise Development.

The Sheltons have been residents of the Cary, Apex, and Holly Springs area for over 30 years. Becky spent the majority of her career as a Sales and Catering Manager for a Hotel & Convention Center in the Research Triangle Park. She was recently employed in an administration role for the Public School System, and later with White Electrical in Apex. Steve is a CPA and previously worked in Public Accounting. He has been in health care Finance, primarily non-profits, for the past 14 years. The Sheltons will be joining two other Caring Transitions owners in the Raleigh area.

Now, with more and more qualified and passionate franchisees like the Sheltons signing on to join the system, Fabik says Caring Transitions shows no signs of slowing down.

“We know that we have a great brand and that Caring Transitions ownership can be a great fit for someone who is tired of their corporate job and wants control of their own destiny, wants to own a business that is truly making a difference in communities or wants to apply their skill set to working in the senior or auction space,” Fabik said. “Now, we want to accelerate growth because we believe there should be a Caring Transitions location in every market to serve seniors and their families through life’s stages.”

Caring Transitions can still accommodate several more owners in the Raleigh area.

Caring Transitions has identified these states as priorities for franchise development: Colorado, Connecticut, Florida, Maine, Massachusetts, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, Pennsylvania, Rhode Island, Texas, and Vermont.

Fees to open a Caring Transitions range from $58,912 to $82,712.

To learn more about franchising with Caring Transitions, visit https://strategicfranchising.com/caring-transitions/.

ABOUT CARING TRANSITIONS:

Caring Transitions provides older adults and their families with the most trusted, respected, and comprehensive downsizing, right-sizing, estate sales, online auctions, and move management solutions in the industry. Founded in 2006, the brand is committed to helping people in a compassionate and caring manner during life’s many transitions while providing a total and easy solution for clients in their time of need. Through their proprietary online sales platform, CTBIDS, Caring Transitions also prepares clients for the process of liquidating assets through their own online estate sales auction site. With over 250 locations, Caring Transitions’ compassionate, experienced professionals minimize stress and relieve the burdens of life’s transitions.

To learn more visit https://www.caringtransitions.com/

Share article on social media or email:

Reliefband® State of Nausea Study Reveals More Than Three-Quarters of Americans Are Prevented from Enjoying Life As a Result of Regular Nausea


“Nausea symptoms are felt everywhere – the mouth, throat, chest, stomach, or throughout your entire body,” explained Rich Ransom, President & CEO at Reliefband. “Our research shows that individuals suffering from nausea avoid social gatherings, certain foods, and outdoor activities.”

Reliefband®, an innovator in wearable technology that prevents and treats nausea and vomiting, has released its First Annual State of Nausea study. According to the survey findings, nausea is epidemic in the United States, with 73% of Americans reporting that they suffer from nausea regularly. Of those who suffer from nausea, 76% stated that their symptoms prevent them from enjoying life to the fullest.

Released on National Stop Nausea Day, the study sheds light on the magnitude of the problem and its far-reaching consequences. 31% of Americans reported experiencing nausea every day, 26% at least once weekly, and 16% once each month. Making matters worse, more than half of the respondents (55%) indicated that they had yet to find an effective solution for their condition. This underscores previous research by Reliefband in 2020 that found sufferers often rely on home remedies, holistic techniques, over the counter and prescription medications, behavior modification, or just suffer with the condition doing nothing at all.

“Nausea is too often trivialized. The reality is that it ruins plans and leads to missed opportunities,” explained Rich Ransom, President, and CEO at Reliefband. “Nausea symptoms are felt everywhere – the mouth, throat, chest, stomach, or throughout your entire body. This robs sufferers of motivation, productivity, and sleep. It also hinders plans and life experiences. Everyday activities become more complicated, and our research shows that individuals suffering from nausea avoid social gatherings, certain foods, and outdoor activities such as boating, fishing, and skiing.”

The study revealed how nausea can affect daily life in many unpleasant ways. More than 18% of respondents reported that their nausea actively hindered their ability to travel, while some could not socialize (3.2%) or even work (2.9%). These findings highlight how nausea extends beyond mere inconvenience for a large majority of the U.S. population.

When describing the intensity of their nausea on a scale of 1 to 10 (10 being unbearable), “7” was the number used by most respondents to rate how overbearing their nausea is. 58% said their discomfort level was seven through 10 on the scale. This echoes earlier research conducted by Reliefband, in which more than half of nausea sufferers (54%) said they experienced moderate to severe symptoms.

Most nausea was reportedly caused by motion sickness: 49.4% of respondents attributed their symptoms to transport, including seasickness (26.0%), carsickness (11.9%), trainsickness (9.6%), and airsickness (1.9%). Other motion-related triggers mentioned by respondents included virtual-reality gaming (9.2%) and amusement park rides (1.6%).

Other common causes of nausea reported in the study included health and mental health issues such as morning sickness, anxiety, chemotherapy treatment, migraines, and post-operative effects. Concerning morning sickness, nausea, and vomiting affect up to 80% of pregnant women, according to a study published by the National Institutes of Health. Taking into account that 3.7 million babies were born in the U.S. in 2022, morning sickness affected nearly three million expectant mothers last year alone.

Reliefband’s First Annual State of Nausea study employed an online survey to collect data from 5,300 U.S. respondents. The survey was completed in December 2022 and consisted of a diverse group of consumers, with 82% of respondents evenly distributed between 25 and 65 years of age.

National Stop Nausea Day is observed every year in the U.S. on the third Tuesday in May. The purpose of the day is to give a voice to nausea sufferers, which affects millions of Americans daily. This day is intended to raise awareness of the causes of nausea, its pervasiveness among Americans, and to create a dialog on innovative treatment options. In observance of National Stop Nausea Day on May 16th, Reliefband’s entire line of anti-nausea wearables are $50 off when using promo code “STOP” at http://www.reliefband.com.

Reliefband is committed to addressing the urgent issue of nausea with wearable therapeutic technology that transforms how nausea and vomiting are managed. Reliefband devices use FDA-cleared, patented neuromodulation technology to target the underlying causes of nausea and provide fast, drug-free relief. Reliefband’s products gently stimulate the median nerve on the underside of the wrist, rebalancing the signals between the brain and the stomach. Reliefband wearables effectively reduce symptoms of nausea and vomiting due to motion sickness, morning sickness during pregnancy, chemotherapy, anxiety, hangovers, physician-diagnosed migraines, and as an adjunct to antiemetics in treating post-operative nausea.

About Reliefband

Reliefband is a world leader in neuromodulation and wearable technology. The company’s patented, clinically proven wearable solution quickly prevents and effectively treats nausea and vomiting. Its unique, FDA-cleared neuromodulation technology was originally developed for use in hospitals and alters nerve activity through targeted delivery of gentle pulses to the underside of the wrist to “turn off” feelings of nausea and vomiting. Reliefband is a drug-free alternative that eliminates the discomfort associated with nausea and vomiting. The Reliefband wearable solution has been an industry leader for more than 20 years and is available OTC, at Reliefband.com and Amazon.com. For more information, visit http://www.Reliefband.com.

Share article on social media or email: